Brief: Morphosys Says Pelabresib Improves All Four Hallmarks Of Myelofibrosis In Phase 3 Manifest-2 Study

Morphosys AG

11/12/2023 24:40

Dec 10 (Reuters) - MorphoSys AG  MORG.DE :
    * PELABRESIB IMPROVES ALL FOUR HALLMARKS OF MYELOFIBROSIS IN
PHASE
3 MANIFEST-2 STUDY
    * PELABRESIB, RUXOLITINIB COMBINATION SIGNIFICANTLY REDUCED
SPLEEN
SIZE, WITH SVR35 RESPONSE RATE NEARLY DOUBLE THAT OF PLACEBO
PLUS RUXOLITINIB
    * SHOWED STRONG POSITIVE TREND IN REDUCING SYMPTOM
BURDEN,TWOFOLD
INCREASE IN PATIENTS ACHIEVING BOTH SVR35, TSS50 VERSUS PLACEBO
PLUS RUXOLITINIB
    * DEMONSTRATED SAFETY RESULTS CONSISTENT WITH PRIOR CLINICAL
TRIALS, WITH FEWER GRADE ≥3 ADVERSE EVENTS COMPARED WITH PLACEBO
PLUS RUXOLITINIB
    * PREPARING REGULATORY FILINGS WITH INTENTION OF SUBMITTING
APPLICATIONS TO U.S. FDA AND EUROPEAN MEDICINES AGENCY IN MIDDLE
OF 2024

Source text for Eikon:  ID:nBw6YyPdCa 
Further company coverage:  MORG.DE 

 ((Reuters.Briefs@thomsonreuters.com;))